PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate the effect of androgen deprivation therapy (ADT) on health-related quality of life (HRQOL) in Asian men with all stages of prostate cancer.
METHODS: READT (real-life evaluation of the effect of ADT in prostate cancer patients in Asia) was a multi-center, prospective observational study involving six sites across four Asian populations. We enrolled eligible prostate cancer patients, who opted for ADT alone or in combination without prior neoadjuvant or adjuvant ADT within 12 months. The EuroQoL-5 dimensions, 5 level scale (EQ-5D-5L) utility index scores and visual analog scale (VAS) were evaluated at baseline, month 6 and month 12.
RESULTS: A total of 504 patients were recruited into READT between September 2016 and May 2020 with 52.9% diagnosed with metastatic prostate cancer. The EQ-5D-5L was evaluable in 442/504 (87.7%) of patients. Overall baseline EQ-5D-5L utility index score was 0.924 (interquartile range [IQR] 0.876-1.000). We observed a statistically significant difference in baseline EQ-5D-5L utility index score among different populations with a median EQ-5D-5L utility index score of 1 for Taiwan & Hong Kong, 0.897 for China and 0.838 for Malaysia. Similar trend was observed throughout multiple treatment time-points. Stage IV prostate cancer were significantly associated with a lower baseline EQ-5D-5L utility index score compared to stage I-III prostate cancer, producing a median disutility value of -0.080. Participants had a high median VAS (80, IQR 70-90), indicating good overall health on average during ADT initiation.
CONCLUSIONS: The study highlights the differences in health state utility index scores among various Asian prostate cancer patients receiving ADT at real-world setting. Our findings will be informative and useful in cost-effectiveness evaluation and policy decision making.
METHODS: READT (real-life evaluation of the effect of ADT in prostate cancer patients in Asia) was a multi-center, prospective observational study involving six sites across four Asian populations. We enrolled eligible prostate cancer patients, who opted for ADT alone or in combination without prior neoadjuvant or adjuvant ADT within 12 months. The EuroQoL-5 dimensions, 5 level scale (EQ-5D-5L) utility index scores and visual analog scale (VAS) were evaluated at baseline, month 6 and month 12.
RESULTS: A total of 504 patients were recruited into READT between September 2016 and May 2020 with 52.9% diagnosed with metastatic prostate cancer. The EQ-5D-5L was evaluable in 442/504 (87.7%) of patients. Overall baseline EQ-5D-5L utility index score was 0.924 (interquartile range [IQR] 0.876-1.000). We observed a statistically significant difference in baseline EQ-5D-5L utility index score among different populations with a median EQ-5D-5L utility index score of 1 for Taiwan & Hong Kong, 0.897 for China and 0.838 for Malaysia. Similar trend was observed throughout multiple treatment time-points. Stage IV prostate cancer were significantly associated with a lower baseline EQ-5D-5L utility index score compared to stage I-III prostate cancer, producing a median disutility value of -0.080. Participants had a high median VAS (80, IQR 70-90), indicating good overall health on average during ADT initiation.
CONCLUSIONS: The study highlights the differences in health state utility index scores among various Asian prostate cancer patients receiving ADT at real-world setting. Our findings will be informative and useful in cost-effectiveness evaluation and policy decision making.
摘要：
目的：探讨雄激素剥夺治疗（ADT）对亚裔前列腺癌患者健康相关生活质量（HRQOL）的影响。
方法：READT（亚洲前列腺癌患者ADT效果的真实评估）是一个多中心，前瞻性观察性研究，涉及四个亚洲人群的六个地点。我们招募了符合条件的前列腺癌患者，选择单独或联合使用ADT，而在12个月内没有新辅助或辅助ADT。EuroQoL-5维度，5级量表（EQ-5D-5L）效用指数评分和视觉模拟量表（VAS）在基线时进行评估，6月和12月。
结果：在2016年9月至2020年5月期间，共有504名患者被纳入READT，其中52.9％被诊断为转移性前列腺癌。在442/504（87.7％）的患者中可评估EQ-5D-5L。总体基线EQ-5D-5L效用指数评分为0.924(四分位距[IQR]0.876-1.000)。我们观察到不同人群之间基线EQ-5D-5L效用指数得分的统计学差异，台湾和香港的EQ-5D-5L效用指数中位数为1，中国为0.897，马来西亚为0.838。在多个处理时间点观察到类似的趋势。与I-III期前列腺癌相比，IV期前列腺癌与较低的基线EQ-5D-5L效用指数得分显着相关。产生的中值无效性值为-0.080。参与者有较高的中位数VAS(80，IQR70-90)，表明ADT启动期间的整体健康状况平均良好。
结论：该研究强调了在现实世界中接受ADT的各种亚洲前列腺癌患者在健康状态效用指数评分方面的差异。我们的发现将对成本效益评估和政策决策提供信息和有用。
方法：READT（亚洲前列腺癌患者ADT效果的真实评估）是一个多中心，前瞻性观察性研究，涉及四个亚洲人群的六个地点。我们招募了符合条件的前列腺癌患者，选择单独或联合使用ADT，而在12个月内没有新辅助或辅助ADT。EuroQoL-5维度，5级量表（EQ-5D-5L）效用指数评分和视觉模拟量表（VAS）在基线时进行评估，6月和12月。
结果：在2016年9月至2020年5月期间，共有504名患者被纳入READT，其中52.9％被诊断为转移性前列腺癌。在442/504（87.7％）的患者中可评估EQ-5D-5L。总体基线EQ-5D-5L效用指数评分为0.924(四分位距[IQR]0.876-1.000)。我们观察到不同人群之间基线EQ-5D-5L效用指数得分的统计学差异，台湾和香港的EQ-5D-5L效用指数中位数为1，中国为0.897，马来西亚为0.838。在多个处理时间点观察到类似的趋势。与I-III期前列腺癌相比，IV期前列腺癌与较低的基线EQ-5D-5L效用指数得分显着相关。产生的中值无效性值为-0.080。参与者有较高的中位数VAS(80，IQR70-90)，表明ADT启动期间的整体健康状况平均良好。
结论：该研究强调了在现实世界中接受ADT的各种亚洲前列腺癌患者在健康状态效用指数评分方面的差异。我们的发现将对成本效益评估和政策决策提供信息和有用。
